Literature DB >> 26374678

Harmonization and streamlining of research oversight for pragmatic clinical trials.

P Pearl O'Rourke1, Judith Carrithers2, Bray Patrick-Lake3, Todd W Rice4, Jeremy Corsmo5, Raffaella Hart6, Marc K Drezner7, John D Lantos8.   

Abstract

The oversight of research involving human participants is a complex process that requires institutional review board review as well as multiple non-institutional review board institutional reviews. This multifaceted process is particularly challenging for multisite research when each site independently completes all required local reviews. The lack of inter-institutional standardization can result in different review outcomes for the same protocol, which can delay study operations from start-up to study completion. Hence, there have been strong calls to harmonize and thus streamline the research oversight process. Although the institutional review board is only one of the required reviews, it is often identified as the target for harmonization and streamlining. Data regarding variability in decision-making and interpretation of the regulations across institutional review boards have led to a perception that variability among institutional review boards is a primary contributor to the problems with review of multisite research. In response, many researchers and policymakers have proposed the use of a single institutional review board of record, also called a central institutional review board, as an important remedy. While this proposal has merit, the use of a central institutional review board for multisite research does not address the larger problem of completing non-institutional review board institutional review in addition to institutional review board review—and coordinating the interdependence of these reviews. In this article, we describe the overall research oversight process, distinguish between institutional review board and institutional responsibilities, and identify challenges and opportunities for harmonization and streamlining. We focus on procedural and organizational issues and presume that the protection of human subjects remains the paramount concern. Suggested modifications of institutional review board processes that focus on time, efficiency, and consistency of review must also address what effect such changes have on the quality of review. We acknowledge that assessment of quality is difficult in that quality metrics for institutional review board review remain elusive. At best, we may be able to assess the time it takes to review protocols and the consistency across institutions.
© The Author(s) 2015.

Entities:  

Keywords:  Central institutional review board; human research protection program; institutional review boards; pragmatic clinical trials; research oversight

Mesh:

Year:  2015        PMID: 26374678      PMCID: PMC4592396          DOI: 10.1177/1740774515597685

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  29 in total

1.  Variation in institutional review board responses to a standard protocol for a multicenter clinical trial.

Authors:  T O Stair; C R Reed; M S Radeos; G Koski; C A Camargo
Journal:  Acad Emerg Med       Date:  2001-06       Impact factor: 3.451

2.  Addressing low-risk comparative effectiveness research in proposed changes to US federal regulations governing research.

Authors:  Nancy Kass; Ruth Faden; Sean Tunis
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

3.  Institutional review board variability in minimal-risk multicenter urogynecology studies.

Authors:  Heidi S Harvie; Lior Lowenstein; Tola B Omotosho; Tatiana Sanses; Stephanie Molden; Janet Hardy; Linda Brubaker
Journal:  Female Pelvic Med Reconstr Surg       Date:  2012 Mar-Apr       Impact factor: 2.091

4.  The paradoxical problem with multiple-IRB review.

Authors:  Jerry Menikoff
Journal:  N Engl J Med       Date:  2010-10-13       Impact factor: 91.245

Review 5.  Institutional review boards and multisite studies in health services research: is there a better way?

Authors:  Jennifer L Gold; Carolyn S Dewa
Journal:  Health Serv Res       Date:  2005-02       Impact factor: 3.402

6.  Quality-improvement research and informed consent.

Authors:  Franklin G Miller; Ezekiel J Emanuel
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

Review 7.  Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform.

Authors:  George Silberman; Katherine L Kahn
Journal:  Milbank Q       Date:  2011-12       Impact factor: 4.911

8.  Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial.

Authors:  Brian T Helfand; Anne K Mongiu; Claus G Roehrborn; Robert F Donnell; Reginald Bruskewitz; Steven A Kaplan; John W Kusek; Laura Coombs; Kevin T McVary
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

9.  Variation among institutional review boards in evaluating the design of a multicenter randomized trial.

Authors:  A R Stark; J E Tyson; P L Hibberd
Journal:  J Perinatol       Date:  2009-10-01       Impact factor: 2.521

10.  How variability in the institutional review board review process affects minimal-risk multisite health services research.

Authors:  Laura A Petersen; Kate Simpson; Richard Sorelle; Tracy Urech; Supicha Sookanan Chitwood
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

View more
  13 in total

Review 1.  Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative.

Authors:  Laura M Dember; Patrick Archdeacon; Mahesh Krishnan; Eduardo Lacson; Shari M Ling; Prabir Roy-Chaudhury; Kimberly A Smith; Michael F Flessner
Journal:  J Am Soc Nephrol       Date:  2016-07-11       Impact factor: 10.121

2.  Lessons Learned From a Practice-Based, Multisite Intervention Study With Nurse Participants.

Authors:  Christopher R Friese; Kari Mendelsohn-Victor; Pamela Ginex; Carol M McMahon; Alex J Fauer; Marjorie C McCullagh
Journal:  J Nurs Scholarsh       Date:  2017-01-18       Impact factor: 3.176

3.  Harms, benefits, and the nature of interventions in pragmatic clinical trials.

Authors:  Joseph Ali; Joseph E Andrews; Carol P Somkin; C Egla Rabinovich
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

4.  Exploring the ethical and regulatory issues in pragmatic clinical trials.

Authors:  Robert M Califf; Jeremy Sugarman
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

5.  Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.

Authors:  Orly Vardeny; Adrian F Hernandez; Lauren W Cohen; Amy Franklin; Mina Baqai; Sarah Palmer; Barbara E Bierer; Nichelle Cobb
Journal:  Clin Trials       Date:  2019-03-13       Impact factor: 2.486

6.  Responding to signals of mental and behavioral health risk in pragmatic clinical trials: Ethical obligations in a healthcare ecosystem.

Authors:  Joseph Ali; Stephanie R Morain; P Pearl O'Rourke; Benjamin Wilfond; Emily C O'Brien; Christina K Zigler; Karen L Staman; Kevin P Weinfurt; Jeremy Sugarman
Journal:  Contemp Clin Trials       Date:  2022-01-05       Impact factor: 2.226

7.  Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.

Authors:  Carole A Federico; Patrick J Heagerty; John Lantos; Pearl O'Rourke; Vasiliki Rahimzadeh; Jeremy Sugarman; Kevin Weinfurt; David Wendler; Benjamin S Wilfond; David Magnus
Journal:  Contemp Clin Trials       Date:  2022-02-15       Impact factor: 2.261

8.  Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.

Authors:  Kevin P Weinfurt; Adrian F Hernandez; Gloria D Coronado; Lynn L DeBar; Laura M Dember; Beverly B Green; Patrick J Heagerty; Susan S Huang; Kathryn T James; Jeffrey G Jarvik; Eric B Larson; Vincent Mor; Richard Platt; Gary E Rosenthal; Edward J Septimus; Gregory E Simon; Karen L Staman; Jeremy Sugarman; Miguel Vazquez; Douglas Zatzick; Lesley H Curtis
Journal:  BMC Med Res Methodol       Date:  2017-09-18       Impact factor: 4.615

Review 9.  Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation.

Authors:  Cory E Goldstein; Charles Weijer; Jamie C Brehaut; Dean A Fergusson; Jeremy M Grimshaw; Austin R Horn; Monica Taljaard
Journal:  BMC Med Ethics       Date:  2018-02-27       Impact factor: 2.652

10.  Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol.

Authors:  Stuart G Nicholls; Kelly Carroll; Jamie Brehaut; Charles Weijer; Spencer Phillips Hey; Cory E Goldstein; Merrick Zwarenstein; Ian D Graham; Joanne E McKenzie; Lauralyn McIntyre; Vipul Jairath; Marion K Campbell; Jeremy M Grimshaw; Dean A Fergusson; Monica Taljaard
Journal:  BMC Med Ethics       Date:  2018-11-20       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.